- Home
- GMM vs RFL Comparison
GMM vs RFL Comparison
Compare GMM & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GMM | RFL |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 54.4M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GMM | RFL |
|---|---|---|
| Price | $1.26 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.3K | ★ 143.0K |
| Earning Date | 08-18-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $48,171,048.00 | $1,029,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.72 | ★ N/A |
| Revenue Growth | 41.74 | ★ 47.63 |
| 52 Week Low | $1.23 | $1.17 |
| 52 Week High | $4.97 | $3.19 |
Technical Indicators
Market Signals| Indicator | GMM | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 43.01 |
| Support Level | $1.28 | $1.21 |
| Resistance Level | $1.41 | $1.60 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 28.25 | 13.95 |
Price Performance
Historical ComparisonAbout GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.